IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by New York Life Investment Management LLC

New York Life Investment Management LLC raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the 4th quarter, Holdings Channel reports. The fund owned 23,086 shares of the medical research company’s stock after acquiring an additional 81 shares during the period. New York Life Investment Management LLC’s holdings in IQVIA were worth $4,537,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Smith Group Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth $1,616,000. Simplify Asset Management Inc. lifted its stake in shares of IQVIA by 67.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,637 shares of the medical research company’s stock worth $2,284,000 after acquiring an additional 3,894 shares during the period. Nordea Investment Management AB lifted its stake in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the period. Hickory Asset Management Inc. acquired a new stake in shares of IQVIA in the 4th quarter worth $941,000. Finally, Fifth Third Bancorp lifted its stake in shares of IQVIA by 13.0% in the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock worth $2,590,000 after acquiring an additional 1,521 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Truist Financial restated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. UBS Group reduced their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. The Goldman Sachs Group reduced their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research note on Monday, February 3rd. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Stock Performance

Shares of NYSE IQV opened at $188.89 on Friday. The company has a market cap of $33.26 billion, a PE ratio of 25.19, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48. IQVIA Holdings Inc. has a 12 month low of $184.66 and a 12 month high of $261.73. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50-day simple moving average of $199.13 and a 200-day simple moving average of $214.96.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.